Role of the Fas/Fas-L system in the immune response to tumors and the resistance to cytotoxic drugs;Le systeme Fas/Fas-ligand: Implications dans la reponse immunitaire antitumorale et dans l'activite des agents cytotoxiques

Bulletin du Cancer

Volumn 85, Issue 8, 1998, Pages 685-694

  Solary, Éric ^a   Micheau, Olivier ^a   Dimanche Boitrel, Marie Thérèse ^a   Martin, François ^a  

^a UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

Apoptosis; Fas receptor; Fas L

Indexed keywords

CYTOTOXIC AGENT; FAS ANTIGEN; FAS LIGAND; PROTEIN BCL 2; PROTEIN KINASE; TUMOR NECROSIS FACTOR; ANTINEOPLASTIC AGENT; TUMOR NECROSIS FACTOR RECEPTOR;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; DRUG CYTOTOXICITY; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; ANIMAL; DRUG EFFECT; DRUG POTENTIATION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MOUSE; NEOPLASM; PHYSIOLOGY; RADIATION EXPOSURE;

ANIMALS; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; HUMANS; IMMUNE TOLERANCE; LYMPHOCYTE ACTIVATION; MICE; NEOPLASMS; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 0032134891     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (102)

1. Yonehara S, Ishii A, Yonehara MA. Cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 1989; 169: 1747-56.
2. Trauth BC, Klas C, Peters AMJ, Matzuku S, Möller P, Falk W, et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989; 245: 301-15.
3. Nagata S. Apoptosis by death factor. Cell 1997; 88: 355-65.
4. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas-ligand-induced apoptosis as a mechanism of immune privilege. Science 1995; 270: 1189-92.
5. Hahne M, Renno T, Schroeter M, Irmler M, French L, Bornard T, et al. Activated B cells express functional Fas-ligand. Eur J Immunol 1996; 26: 721-4.
6. Friesen C, Herr I, Krammer PH, Debatin KM. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nature Med 1996; 2: 574-7.
7. Müller M, Strand S, Hug H, Heinemann EM, Walczak H, Hofmann WJ, et al. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest 1997; 99: 403-13.
8. Reap EA, Roof K, Maynor K, Borrero M, Booker J, Cohen PL. Radiation- and stress-induced apoptosis: a role for Fas/Fas-ligand interactions. Proc Natl Acad Sci USA 1997; 94: 5750-5.
9. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993 ; 364 : 806-9.
10. Micheau O, Solary E, Hammann A, Martin F, Dimanche-Boitrel MT. Sensitization of cancer cells treated with cytotoxic drugs to Fas-mediated cytotoxicity. J Natl Cancer Inst 1997; 89: 783-9.
11. Nagata S, Golstein P. The Fas death factor. Science 1995; 267: 1449-56.
12. Miyawaki T, Uehara T, Nibu R, Tsuji T, Yachie A, Yonehara S, et al. Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood. J Immunol 1992; 149: 3753-8.
13. Dirks W, Schöne S, uphoff C, Quentmeier H, Pradella S, Drexler HG. Expression and function of CD95 (Fas/APO-1) in leukemia-lymphoma tumour lines. Br J Haematol 1997; 96: 584-93.
14. Keane MM, Ettenberg SA, Lowrey GA, Russell EK, Lipkowitz S. Fas expression and function in normal and malignant breast cell lines. Cancer Res 1996; 56: 4791-8.
15. Landowski TH, Gleason-Guzman MC, Dalton WS. Selection for drug resistance to Fas-mediated apoptosis. Blood 1997; 89: 1854-61.
16. Bonnotte B, Favre N, Reveneau S, Micheau O, Droin N, Garrido C, et al. Sensitization of tumor cells to Fas-mediated cell death by butyrate. Cell Death Diff 1998 (in press).
17. Turley JM, Fu T, Ruscetti FW, Mikovits JA, Bertolette DC 3rd, Birchenall-Roberts MC. Vitamine E succinate induces Fas-mediated apoptosis in estrogen receptor-negative human breast cancer cells. Cancer Res 1997; 57: 881-90.
18. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas-ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75: 1169-78.
19. Kayagaki N, Kawasaki A, Ebata T, Ohmoto H, Ikeda S, Inoue S, et al. Metalloproteinase-mediated release of human Fas-ligand. J Exp Med 1995; 182: 1777-83.
20. Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995; 81: 505-12.
21. Boldin MP, Varfolomeev EE, Pancer Z, Mett IL, Camonis JH, Wallach D. A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J Biol Chem 1995; 270: 7795-8.
22. Muzio M, Chinnaiyan AM, Kischkel FC, O'Rourke K, Shevchenko A, Ni J, et al. FLICE, a novel FADD-Homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 1996; 85: 817-27.
23. Boldin MP, Goncharov TM, Goltsev YV, Wallach D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1-and TNF receptor-induced cell death. Cell 1996; 85: 803-15.
24. Srinivasula SM, Ahmad M, Fernandes-Alnemri T, Litwack G, Alnemri ES, Molecular ordering of the Fas-apoptotic pathway: the Fas/APO-1 protease Mch5 is a crmA-inhibitable protease that activates multiple Ced-3/ICE-like cysteine proteases. Proc Natl Acad Sci USA 1996; 93: 14486-91.
25. Vincenz C, Dixit VM. Fas-associated death domain protein interleukin-1-β-converting enzyme 2 (FLICE2), an ICE/Ced-3 homologue, is proximally involved in CD95- and p55-mediated death signaling. J Biol Chem 1997; 272: 6578-83.
26. Yang X, Khosravi-Far R, Chang HY, Baltimore D. Daxx, a novel Fas-binding protein that activates JNK and apoptosis. Cell 1997; 89: 1067-76.
27. Brenner B, Koppenhoefer U, Weinstock C, Linderkamp O, Lang F, Gulbins E. Fas- or ceramide-induced apoptosis is mediated by a Rac-1-regulated activation of Jun N-terminal kinase/p38 kinases and GADD153. J Biol Chem 1997; 272: 22173-81.
28. Eymin B, Dubrez L, Allouche M, Solary E. Increased gadd153 messenger RNA level is associated with apoptosis in human leukemic cells treated with etoposide. Cancer Res 1997; 57: 686-95.
29. Gill BM, Nishikata H, Chan G, Delovitch TL, Ochi A. Fas ceramides Fas antigen and sphyngomyelin-ceramide turnover-mediated signaling: role in the life and death of T lymphocytes. Immunol reviews 1994; 142: 113-25.
30. Spiegel S, Foster D, Kolesnick R. Signal transduction through lipid second messengers. Curr Opin Cell Biol 1996; 8: 159-67.
31. Sillence DJ, Allan D. Evidence against an early signalling role for ceramide in Fas-mediated apoptosis. Biochem J 1997; 324: 29-32.
32. Jaffrézou JP, Levade T, Bettaieb A, Andrieu N, Bezombes C, Maestre N, et al. Daunorubicin-induced apoptosis: triggering of ceramide generation through sphingomyelin hydrolysis. EMBO J 1996; 15: 2417-24.
33. Tewari M, Dixit VM. Fas- and tumor necrosis factor-induced apoptosis is inhibited by the poxvirus crmA gene product. J Biol Chem 1995; 270: 3255-60.
34. Miura M, Friedlander RM, Yuan J. Tumor necrosis factor-induced apoptosis is mediated by a crmA-sensitive cell death pathway. Proc Natl Acad Sci USA 1995; 92: 8313-22.
35. Enari M, Hug H, Nagata S. Involvement of an ICE-like protease in Fas-mediated apoptosis. Nature 1995; 375: 78-81.
36. Chow SC, Weis M, Kass GEN, Holmström TH, Eriksson JE, Orrenius S. Involvement of multiple proteases during Fas-mediated apoptosis in T lymphocytes. FEBS Letters 1995; 364: 134-8.
37. Enari M, Talanian RV, Wong WW, Nagata S. Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis. Nature 1996; 380: 723-6.
38. Dubrez L, Savoy I, Hammann A, Solary É. Pivotal role of a DEVD-sensitive step in etoposide-induced and Fas-mediated apoptotic pathways. EMBO J 1996; 15: 5504-12.
39. Schlegel J, Peters I, Orrenius S. Isolation and partial characterization of a protease involved in Fas-induced apoptosis. FEBS Letters 1995; 364: 139-42.
40. Darmon AJ, Bleackley RC. An interleukin-1-beta converting enzyme-like protease is a key component of Fas-mediated apoptosis. J Biol Chem 1996; 271: 21699-702.
41. Itoh N, Tsujimoto Y, Nagata S. Effect of Bcl-2 on Fas antigen-mediated cell death. J Immunol 1993; 151: 621-7.
42. Debatin KM, Krammer PH. Resistance to APO-1 (CD95) induced apoptosis in T-ALL is determined by a Bcl-2 independent anti-apoptotic program. Leukemia 1995; 9: 815-20.
43. Sato T, Irie S, Kitada S, Reed JC. FAP-1: a protein tyrosine phosphatase that associates with Fas. Science 1995; 268: 411-5.
44. Yanagisawa J, Takahashi M, Kanki H, Yano-Yanagisawa H, Tazunoki T, Sawa E, et al. The molecular interaction of Fas and FAP-1. A tripeptide blocker of human Fas interaction with FAP-1 promotes Fas-induced apoptosis. J Biol Chem 1997; 272: 8539-45.
45. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V. Inhibition of death receptor signals by cellular FLIP. Nature 1997; 388: 190-5.
46. Shu HB, Halpin DR, Goeddel DV. Casper is a FADD- and caspase-related inducer of apoptosis. Immunity 1997; 6: 751-63.
47. Srinivasula SM, Ahmad M, Ottilie S, Bullrich F, Banks S, Wang Y, et al. FLAME-1, a novel FADD-like anti-apoptotic molecule that regulates Fas/TNFR1-induced apoptosis. J Biol Chem 1997; 272: 18542-5.
48. Bertin J, Armstrong RC, Ottilie S, Martin DA, Wang Y, Banks S, et al. Death effector domain-containing herpesvirus and poxvirus proteins inhibit both Fas- and TNFR1-induced apoptosis. Proc Natl Acad Sci USA 1997; 94: 1172-6.
49. Hu S, Vincenz C, Ni J, Gentz R, Dixit VM. I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1 and CD95-induced apoptosis. J Biol Chem 1997; 272: 17255-7.
50. Malinin NL, Boldin MP, Kovalenko AV, Wallach D. MAP3K-related kinase involved in NF-κB induction by TNF, CD95 and IL1. Nature 1997; 385: 540-4.
51. Clem RJ, Miller LK. Control of programmed cell death by the baculovirus genes p35 and iap. Mol Cell Biol 1994; 14: 5212-22.
52. Mackenzie IR, Carrigan DR, Wiley CA. Chronic myelopathy associated with human herpesvirus-6. Neurology 1995; 45: 2015-7.
53. Kitson J, Raven T, Jiang YP, Goeddel DV, Giles KM, Pun KT, et al. A death-domain-containing receptor that mediates apoptosis. Nature 1996; 384: 372-5.
54. Chinnaiyan AM, O'Rourke K, Yu GL, Lyons RH, Garg M, Duan DR, et al. Signal transduction by DR3, a death domain-containing receptor related to TNFR1 and CD95. Science 1996; 274: 990-2.
55. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3: 373-82.
56. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a novel member of the tumor necrosis factor cytokine family. J Biol Chem 1996; 271: 12687-90.
57. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997; 277: 818-21.
58. Lowin B, Hahne M, Mattmann C, Tschopp J. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 1994; 370: 650-2.
59. Rouvier E, Luciani MF, Golstein P. Fas involvement in Ca(2′)-independent T cell-mediated cytotoxicity. J Exp Med 1993; 177: 195-200.
60. Kagi D, Vignaux F, Ledermann B, Buriki K, Depraetere V, Nagata S, et al. Fas and perforine pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994; 265: 528-30.
61. Vignaux F, Vivier E, Malissen B, Depraetere V, Nagata S, Golstein P. TCR/CD3 coupling to Fas-based cytotoxicity. J Exp Med 1995; 181: 781-6.
62. Montel AH, Bochan MR, Goedel WS, Fas-mediated cytotoxicity remains intact in perforin and granzyme B antisense transfectants of a human NK-like cell line. Cell Immunol 1995; 165: 312-7.
63. Singer GG, Carrera AC, Marshak-Rothstein A, Martinez C, Abbas AK. Apoptosis, Fas and systemic autoimmunity: the MRL-lpr/lpr model. Curr Opin Immunol 1994; 6: 913-20.
64. Takahashi T, Tanaka M, Brannan CI, Jenkins NA, Copeland NG, Suda T, et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas-ligand. Cell 1994; 76: 969-76.
65. Rieux-Laucat F, Le Deist F, Hivroz C, Roberts IA, Debatin KM, Fischer A, et al. Mutations in Fas associated with lymphoproliferative syndrome and autoimmunity. Science 1995; 268: 1347-9.
66. Pensati L, Costanzo A, Ianni A, Accapezzato D, Iorio R, Natoli G, et al. Fas/APO-1 mutations and autoimmune lymphoproliferative syndrome in a patient with type 2 autoimmune hepatitis. Gastroenterology 1997; 113: 1384-9.
67. O'Connell J, O'Sullivan GC, Collins JK, et al. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas-ligand. J Exp Med 1996; 184: 1075-82.
68. Saas P, Walker PR, Hahne M, Quiquerez AL, Schnuriger V, Perrin G, et al. Fas-ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J Clin Invest 1997; 99: 1173-8.
69. Niehans GA, Brunner T, Frizelle SP, Litson JC, Salerno CT, Knapp DJ, et al. Human lung carcinomas express Fas-ligand. Cancer Res 1997; 57: 1007-12.
70. Villunger A, Egle A, Marschitz I, Kos M, Böck G, Ludwig H, et al. Constitutive expression of Fas (APO-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance. Blood 1997; 90: 12-20.
71. Villunger A, Egle A, Kos M, Hartmann BL, Geley S, Kofler K, Greil R. Drug-induced apoptosis is associated with enhanced Fas (APO-1/CD95) ligand expression but occurs independently of Fas (APO-1/CD95) signaling in human T-acute lymphatic leukemia cells. Cancer Res 1997; 57: 3331-4.
72. Zeytun A, Hassuneh M, Nagarkatti M, Nagarkatti PS. Fas-Fas-ligand-based interactions between tumor cells and tumor-specific cytotoxic T lymphocytes: a lethal two-way street. Blood 1997; 90: 1952-9.
73. Seino K, Kayagaki N, Bashuda H, Okumura K, Yagita H. Contribution of Fas-ligand to cardiac allograft rejection. Int Immunol 1997; 8: 1347-54.
74. Seino K, Kayagaki N, Fukao K, Okumura K, Yagita H. Rejection of Fas-ligand-expressing grafts. Transplant Proc 1997; 293: 1092-3.
75. Arai H, Chan SY, Bishop DK, Nabel GJ. Inhibition of the alloantibody response by CD95 ligand. Nature Med 1997; 3: 843-8.
76. Abreu-Martin MT, Vidrich A, Lynch DH, Targan SR. Divergent induction of apoptosis and IL8 secretion in HT29 cells in response to TNFα and ligation of Fas antigen. J Immunol 1995; 155: 4147-54.
77. Möller P, Koretz K, Leithäuser F, Bruderlein S, Henne C, Quentmeier A, et al. Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int J Cancer 1994; 57: 371-7.
78. Hayashi H, Tatebe S, Osaki M, Goto A, Suzuki Y, Ito H. Expression of Fas antigen and its mediation of apoptosis in human gastric cancer cell lines. Jpn J Cancer Res 1997; 88: 49-55.
79. Tomita Y, Kawasaki T, Bilim V, Takeda M, Takahashi K. Tetrapeptide DEVD-aldehyde or YVAD-chloromethylketone inhibits Fas/APO-1(CD95)-mediated apoptosis in renal-cell-cancer cells. Int J Cancer 1996; 68: 132-5.
80. Rohklin OW, Bishop GA, Hostager BS, Waldschmidt TJ, Sidorenko SP, Pavloff N, et al. Fas-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res 1997; 57: 1758-68.
81. Nano R, Barni S, Capelli E. Morphological changes of lymphocytes activated with interleukin-2. Haematologica 1996; 81: 93-4.
82. Kumazawa H, Minamino M, Yukawa N, Hess M. Suppression of natural killer cell activity by serum derived from head and neck cancer patients. Cancer Detect Prev 1995; 19: 494-502.
83. Weller M, Malipiero U, Aguzzi A, Reed JC, Fontana A. Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J Clin Invest 1995; 95: 2633-43.
84. Chauchan D, Pandley P, Ogata A, Teoh G, Treon S, Urashima M, et al. Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism. Oncogene 1997; 15: 837-43.
85. Cheng J, Zhou T, Lin C, Shapiro JP, Brauer MJ, Kiefer MC, et al. Protection from Fas-mediated apoplosis by a soluble form of the Fas molecule. Science 1994; 263: 1759-62.
86. Uslu R, Jewett A, Bonavida B. Sensitization of human ovarian tumor cells by subcytotoxic CDDP to anti-Fas antibody-mediated cytotoxicity and apoptosis. Gynecol Oncol 1996; 62: 282-91.
87. Mizutani Y, Okada Y, Yoshida O, Fukumoto M, Bonavida B. Doxorubicin sensitizes human bladder carcinoma cells to Fas-mediated cytotoxicity. Cancer 1997; 79: 1180-9.
88. Morimoto H, Yonchara S, Bonavida B. Overcoming tumor necrosis factor and drug resistance of human cell lines by combination treatment with anti-Fas antibody and drugs or toxins. Cancer Res 1993; 53: 2591-6.
89. Nakamura S, Takeshima M, Nakamura Y, Ohtake S, Matsuda T. Induction of apoptosis in HL60 leukemic cells by anticancer drugs in combination with anti-Fas monoclonol antibody. Anticancer Res 1997; 17: 173-80.
90. Eischen CM, Kottke TJ, Martins LM, Basi GS, Tung JS, Earnshaw WC, et al. Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas-ligand interactions. Blood 1997; 90: 935-43.
91. Micheau O, Solary E., Hammann A, Martin F, Dimanche-Boitrel MT. Involvment of FADD and caspase-8 in drug-induced cell death, 1998, manuscrit en préparation.
92. Droin N, Dubrez F, Eymin B, Renvoizé C, Breard J, Dimanche-Boitrel MT, et al. Upregulation of CASP genes in human tumor cells undergoing etoposide-induced apoplosis. Oncogene 1998; 16: 2885-94.
93. Kimura H, Yamaguchi Y. A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma. Cancer 1997; 80: 42-9.
94. Fulda S, Sieverts H, Fliesen C, Herr I, Debatin KM. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res 1997; 57: 3823-9.
95. Friesen C, Fulda S, Debatin KM. Deficient activation of the CD95 (APO)-1/Fas) system in drug-resistant cells. Leukemia 1997; 11: 1833-41.
96. Herr I, Wihelm D, Böhler T, Angel P, Debatin KM. Activation of CD95 (APO-1/Fas) signaling by ceramide mediates cancer therapy-induced apoptosis. EMBO J 1997; 16: 6200-8.
97. White K, Grether ME, Abrams JM, Young F, Farrell K, Steller H. Genetic control of programmed cell death in Drosophila. Science 1994; 264: 677-83.
98. Golstein P, Marguet D, Depraetere V. Homology between reaper and the cell death domains of Fas and TNFRI. Cell 1995; 81: 185-6.
99. Efferth T, Fabry U, Osieka R, Anti-Fas/APO-1 monoclonal antibody CH-11 depletes glutathione and kills multidrug-resistant human leukemic cells. Blood Cells Mol Dis 1996; 22: 2-9.
100. Cai Z, Stancou R, Korner M, Chouaib S. Impairement of Fas-antigen expression in adriamycin-resistant but not TNF-resistant MCF7 tumor cells. Int J Cancer 1996; 68: 535-46.
101. Leverkus M, Yaar M, Gilchrest BA. Fas/Fas-ligand interaction contributes to UV-induced apoptosis in human keratinocytes. Exp Cell Res 1997; 232: 255-62.
102. Rehemtulla A, Hamilton CA, Chinnaiyan AM, Dixit VM. Ultraviolet radiation-induced apoptosis is mediated by activation of CD95 (Fas/APO-1). J Biol Chem 1997; 273: 25783-6.